EZH2 Inhibitors via Structural Optimization for Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cancer lack effective inhibitors for Enhancer of Zeste Homolog 2 (EZH2), a protein associated with cancer aggressiveness and progression, as existing EZH2 inhibitors have limitations in specificity and efficacy.
Innovation Solution
Development of specific compounds, represented by Formula (I) and its pharmaceutically acceptable salts, which inhibit EZH2 activity, thereby targeting various types of cancers, including solid tumors and leukemias, by disrupting histone methylation processes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EZH2 inhibitors are used, then some inhibition effect is achieved, but specificity and efficacy are limited
Solution Approach 1:
The patent modifies the chemical structure parameters of EZH2 inhibitors by introducing specific substituents (R1-R6 groups) at defined positions on the core heterocyclic ring system. This structural parameter optimization enhances both the binding affinity (efficacy) and selectivity (specificity) toward EZH2 compared to prior art inhibitors
Solution Approach 2:
The invention creates composite molecular structures combining a core heterocyclic scaffold with various functional groups (pyridine, piperidine, heteroaryl substituents) to achieve synergistic effects that improve both potency and specificity of EZH2 inhibition
2Productivity
If EZH2 activity is inhibited, then cancer cell proliferation decreases and apoptosis increases, but the compounds may affect other cellular processes
Solution Approach 1:
The patent introduces specific local modifications to the inhibitor structure, including particular substituent patterns at R3-R6 positions and specific heteroatom placements, that direct the compound's action specifically toward EZH2's catalytic site while minimizing interactions with other epigenetic enzymes or cellular targets
Data Source
AI summary
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.